Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001377759 | SCV001575172 | likely pathogenic | Cerebral creatine deficiency syndrome | 2020-11-11 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GAMT are known to be pathogenic (PMID: 15108290). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with GAMT-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 2 of the GAMT gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
| Baylor Genetics | RCV003469631 | SCV004198578 | likely pathogenic | Deficiency of guanidinoacetate methyltransferase | 2023-08-22 | criteria provided, single submitter | clinical testing |